

## EGF Theramed Signs Definitive Agreement to Acquire Seedadelic

Vancouver, BC, June 2, 2021 – EGF THERAMED HEALTH CORP. (CSE:TMED / OTC:EVAHF / FRANKFURT: AUHP) (the “Company”) is pleased to announce that it has entered into a definitive share purchase agreement, dated May 31, 2021, pursuant to which it will acquire (the “Proposed Acquisition”) all of the issued and outstanding share capital of Seedadelic Health Services Corp. (“Seedadelic”).

Seedadelic is an alternative medicine company seeking to alleviate the stigma surrounding psychedelic drugs through the distribution of plant seeds, such as *Argyreia Nervosa* (Hawaiian Baby Woodrose) and *Ipomoea Violacea* (Morning Glory), that contain a naturally occurring compound known as LSA (D-lysergic acid amide).

### *Seedadelic*

Seedadelic is a private, Ontario-based company, that plans to operate as a web-based and mobile application, allowing users to register and purchase certain plant seed products online. The seeds are expected to be sold in a dispensary that carries a variety of plant seeds and will be distributed online through e-commerce as well as through brick-and-mortar retailers. The Seedadelic business model anticipates deploying its mobile application (“app”), which can be used as a platform for sellers of Morning Glory and Hawaiian Baby Woodrose seeds to purchasers in locations where such sales are legal. Initially, products are expected to be supplied on the app by Seedadelic, with the expectation that the app will eventually facilitate a dropshipping method of sales, where third-parties sell their legal products on the app. Seedadelic’s current assets are made up of intellectual property and approximately \$450,000 in working capital.

### *About LSA*

The psychedelic medicine market in North America has grown substantially over the last year and is expected to continue in the future with an expanding rate of growth. Lysergic acid amide (also known as ergine, d-lysergic acid amide, d-lysergamide, and “**LSA**”) is a naturally occurring psychedelic substance of the lysergamide class. LSA is an ergot alkaloid and the main psychoactive constituent of morning glory seeds. LSA is chemically related to LSD and is said to produce similar effects. LSA was first described in 1932 as part of an investigation into the alkaloids found in ergot. In 1947, it was synthesized and tested for human activity by Albert Hofmann. The intramuscular administration of a 500-microgram dose produced a “tired, dreamy state with an inability to maintain clear thoughts.” In 1970, LSA was detected as a constituent in Hawaiian Baby Woodrose seeds, which were being ground up into capsules and sold on the street as “mescaline”. Today, LSA is typically consumed via Morning Glory and Hawaiian Baby Woodrose seeds. Unlike most psychedelics, LSA occurring naturally in seeds is legal.

User reports describe the effects of LSA as primarily sedating and dream-like, with a mild to moderate psychedelic component. The psychedelic effects of LSA occur inconsistently and are not directly comparable to the effects of classical psychedelics like LSD, psilocybin mushrooms, or mescaline. LSA is described as primarily bodily and cognitive, with little visual effects.

Like other psychedelics, LSA is not considered to be addictive and some consider it to be a legal alternative to LSD. LSA can be found naturally throughout the forests of this world, whereas LSD is the product of extensive lab work. Morning Glory seeds have a long history of ceremonial use among Mexican tribes, and the seeds are often chewed in order to extract the LSA they contain.

Other psychedelics are currently only in the clinical testing stage and are not available for retail or customers, so no other similar products currently exist in Canada that offer a psychedelic experience while being completely legal. Seedadelic will look to operate in the psychedelic market prior to other services and products becoming available.

### *Transaction Details*

In consideration for the acquisition of all of the issued and outstanding share capital of Seedadelic, the Company is required to issued 15,000,000 common shares (the “**Consideration Shares**”) to the existing shareholders of Seedadelic. Following issuance, the Consideration Shares will be subject to the terms of an escrow agreement, during which time they may not be transferred or sold until a date that is four months after the date that the Company files a Form 51-102F4 Business Acquisition Report on SEDAR in compliance with National Instrument 51-102 – *Continuous Disclosure Obligations* (“**NI 51-102**”). The closing of the Proposed Acquisition is subject to Seedadelic having at least \$450,000 in positive working capital.

The Proposed Acquisition is an arm’s-length transaction as the Company is not a related party to Seedadelic or any of its shareholders. The Proposed Acquisition will not constitute a fundamental change for the Company, nor will it result in a change of control of the Company, with the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Within 75 days of closing the Proposed Acquisition, the Company will file a Form 51-102F4- Business Acquisition Report on SEDAR at the request of the Canadian Securities Exchange and in compliance with NI 51-102. The Proposed Acquisition was approved by a majority of the Company’s disinterested shareholders at the Company’s annual general and special meeting of its shareholders held on April 28, 2021. In connection with the completion of the Proposed Acquisition, the Company will issue 1,500,000 common shares as a finder’s fee to a company that introduced the parties.

### **ABOUT EGF THERAMED HEALTH CORP.**

**(CSE:TMED / OTC:EVAHF / FRANKFURT: AUHP)**

EGF Theramed is a consumer technology company engaged in the provision of biomedical services for treating common health problems. The Company is working to collaborate with other companies for medical technology, equipment protocols and laboratory standard operating procedures. Through the Company’s recent joint venture acquisitions, it has begun to research psilocybin and psychedelic extraction and processing for commercialization.

### **FOR MORE INFORMATION PLEASE CONTACT:**

#### **EGF THERAMED HEALTH CORP.**

#### **Doug McFaul**

Email: [dmcfaul@emprisecapital.com](mailto:dmcfaul@emprisecapital.com)

Telephone: (778) 331 8505

Website: <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

Frankfurt Borse: <https://www.boerse-frankfurt.de/equity/egf-theramed-health-corp>

## **DISCLAIMERS**

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to: Seedadelic’s business plans, including with respect to the establishment and operation of the app and the sale of Hawaiian Baby Woodrose and Morning Glory seeds. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.